Dr. David Reardon, director of Dana-Farber Cancer Institute’s Center for Neuro-Oncology, discusses new targeted therapies, immunomodulators, cancer vaccines, cell therapies, and oncolytic virus therapies currently approved or being explored in clinical trials. #btsm #CRIsummit #immunotherapy https://summit.cancerresearch.org/

00:00- Tamron Hall introduces Dr. David Reardon
00:37- Dr. Reardon discusses brain cancer and immunotherapy
08:08- Brian Brewer leads a Q&A from the audience with Dr. Reardon

Globally, approximately 300,000 men and women are diagnosed with a cancer of the brain and nervous system every year. Although significant advances have been made in understanding the biology of these cancers, the mortality rate has remained steady for more than 30 years. Immunotherapy offers potential new treatment options for this devastating set of diseases. https://www.cancerresearch.org/immuno...

Questions from the audience for Dr. Reardon:
- What are the promising immunotherapy clinical trials for brain cancer right now?
- How does age affect trial eligibility?
- How do I go about getting a second opinion?
- Is there an ideal time for a patient to look into immunotherapy for brain cancer? Is immunotherapy a reasonable option prior to chemotherapy, surgery, or radiation?

Dr. David Reardon is a professor of medicine at Harvard Medical School and currently serves as the director of Dana-Farber Cancer Institute’s Center for Neuro-Oncology. He is an active researcher with special interests in the design and implementation of clinical trials for individuals with brain and spinal tumors, focusing particularly on immunotherapeutics. https://www.cancerresearch.org/en-us/...

The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. https://www.cancerresearch.org/en-us/...

Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.